Trial Profile
COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Registrational; Therapeutic Use
- Acronyms COMBI-AD
- Sponsors GlaxoSmithKline; GSK; Novare Pharmaceuticals; Novartis Pharma A.G.
- 05 Sep 2023 This trial has been completed in Belgium according to European Clinical Trials Database record.
- 03 Sep 2023 This trial has been completed in Greece according to European Clinical Trials Database record.
- 21 Aug 2023 Status changed from active, no longer recruiting to completed.